Work

Abstract PS11-07: Intratumoral activation and phase 1/2 clinical activity of CX-2009, a probody drug conjugate (PDC) targeting CD166

Year: 2021

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.sabcs20-ps11-07

Authors: Joyce F. Liu, Ivan A. Zein, Tam Dang, Susan K. Lyman, Alexander Spira, Nataliya Uboha, Patricia LoRusso, Mary J. Fidler, Funda Meric-Bernstam, Tobias Arkenau, Misako Nagasaka, Luc R. Desnoyers, William M. Kavanaugh, Virginia Paton, Alison Hannah, Valentina Boni

Institutions: Dana-Farber Cancer Institute, CytomX Therapeutics (United States), Virginia Cancer Specialists, University of Wisconsin–Madison, University of Wisconsin Carbone Cancer Center, Yale University, Rush University Medical Center, The University of Texas MD Anderson Cancer Center, Sarah Cannon Research Institute, The Barbara Ann Karmanos Cancer Institute, South Texas Accelerated Research Therapeutics

Language: English

Topic: Monoclonal and Polyclonal Antibodies Research

Subfield: Radiology, Nuclear Medicine and Imaging

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3132671587

Cites:

Cited by: 1

Related to: 10